IMIDomics nabs $16.5m Series A

IMIDomics Inc., a drug discovery company focused on patients with immune-mediated inflammatory diseases, has raised $16.5 million in Series A financing.

IMIDomics Inc., a drug discovery company focused on patients with immune-mediated inflammatory diseases, has raised $16.5 million in Series A financing. DNS Capital led the round with participation from other investors that included Bristol Myers Squibb, The Pritzker Organization and Tao Capital.

Source: Press Release